ABBV vs ASTH

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

ASTH's Piotroski F-Score of 6/9 indicates a stable but not strong financial foundation, with notable weaknesses in profitability and cash flow generation. The absence of an Altman Z-Score raises concern about default risk, particularly given a high debt/equity ratio of 1.96 and negative earnings growth of -97.7% YoY. While the company exhibits explosive revenue growth (99.7% YoY) and strong earnings surprises in recent quarters, these are not sustainable without improving margins and profitability. The stock trades at a forward P/E of 9.64 but a current P/E of 107.00, suggesting a massive valuation disconnect that reflects overpricing relative to current earnings. The Graham Number of $8.19 and intrinsic value of $1.33 imply severe overvaluation, with the current price of $20.33 trading at a significant premium.